Evidence map›Paper›PMID 27157623›Full record

ArticleOncogene2016

Suppression of intestinal tumors by targeting the mitotic spindle of intestinal stem cells.

R Yao, J Oyanagi, Y Natsume, D Kusama, Y Kato, S Nagayama, T Noda

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

R YaoDepartment of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Koto-Ku, Tokyo, Japan.
J OyanagiDepartment of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Koto-Ku, Tokyo, Japan.
Y NatsumeDepartment of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Koto-Ku, Tokyo, Japan.
D KusamaDepartment of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Koto-Ku, Tokyo, Japan.
Y KatoDepartment of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Koto-Ku, Tokyo, Japan.
S NagayamaDepartment of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research (JFCR), Koto-Ku, Tokyo, Japan.
T NodaDepartment of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Koto-Ku, Tokyo, Japan.
Japanese Foundation For Cancer Research · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human colorectal cancer is often initiated by the aberrant activation of Wnt signaling, notably following adenomatous polyposis coli (Apc) inactivation. Recent studies identified adult intestinal stem cells (ISCs) and demonstrated their role as the cells of origin for intestinal tumors. However, the early consequences of aberrant Wnt signaling activation remain to be fully elucidated. Here, using organoid cultures established from conditional knockout mice and in vitro gene ablation, we show that Apc inactivation led to aberrant ISC proliferation and the expansion of the crypt domain. This system was used to evaluate the potential of a cancer-related spindle protein, Tacc3, as a target of cancer therapy, as its disruption led to the suppression of tumor formation in an animal model of intestinal tumors. We found that Tacc3 is required for the proper mitosis of Apc-deficient ISCs, and its disruption significantly attenuated the expansion of the crypt domain. In vivo analysis of corresponding mutant mice demonstrated that Tacc3 disruption led to a significant decrease in tumor number and prolonged survival. These observations demonstrated that Tacc3 is a potential chemotherapeutic target for intestinal tumors by perturbing the aberrant cell proliferation of Apc-deficient ISCs and provides an opportunity for the development of novel cancer prevention and treatment.

Indexed as

Adenomatous Polyposis Coli ProteinAllelesAnimalsCarrier ProteinsDisease Models, AnimalFetal ProteinsGene ExpressionGene Knockout TechniquesIntestinal MucosaIntestinal NeoplasmsMiceMice, TransgenicMicrotubule-Associated ProteinsOrganoidsReceptors, G-Protein-CoupledSpindle ApparatusAdenomatous Polyposis Coli ProteinCarrier ProteinsFetal ProteinsLgr5 protein, mouseMicrotubule-Associated ProteinsReceptors, G-Protein-CoupledTACC3 protein, mouse

Identifiers

PMID27157623
OpenAlexW2346250692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.